Form 4: SAB Biotherapeutics CEO Granted 4.8M Stock Options

SAB Biotherapeutics' CEO and Executive Chairman, Samuel J. Reich, was granted 4.8 million stock options with an exercise price of $2.17, vesting over four years.

Summary

• Samuel J. Reich, CEO and Executive Chairman of SAB Biotherapeutics, Inc. (SABS), was granted 4,800,000 stock options.
• The options have an exercise price of $2.17 per share.
• The transaction date for this grant was August 26, 2025.
• These options are exercisable starting August 26, 2025, and expire on August 26, 2035.
• The grant is made under the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.
• The awards are contingent upon the Company receiving stockholder approval to amend the Plan to increase the number of shares available for issuance.
• The shares underlying the option vest over a four-year period: 1/4 vests on March 1, 2026, and the remaining 3/4 vests pro rata on a monthly basis in 36 equal installments thereafter.

Sentiment

Score: 7

Explanation: The grant of a significant number of stock options to the CEO is generally positive as it aligns management's interests with shareholders for long-term value creation. However, the contingency of shareholder approval and potential future dilution temper the immediate positive impact.

Positives

• The grant of 4.8 million stock options to the CEO and Executive Chairman, Samuel J. Reich, aligns his long-term interests with those of shareholders, incentivizing future stock price appreciation.
• The options are granted at an exercise price of $2.17, suggesting a belief in the company's ability to exceed this value in the future.

Negatives

• The awards are subject to stockholder approval to amend the 2021 Omnibus Equity Incentive Plan, introducing a contingency for the grant's full realization.
• Potential future dilution for existing shareholders if the options are exercised, as 4.8 million new shares of common stock could be issued.

Risks

• **Shareholder Approval Risk:** The options grant is contingent on stockholder approval to amend the 2021 Omnibus Equity Incentive Plan to increase the number of shares available for issuance.
• **Stock Price Performance Risk:** The value of the options is directly tied to the future performance of SAB Biotherapeutics' common stock; if the stock price does not rise above the $2.17 exercise price, the options may not be in-the-money.
• **Dilution Risk:** If the options are exercised, it will result in the issuance of additional common stock, potentially diluting the ownership percentage of existing shareholders.

Future Outlook

The grant of significant stock options to the CEO suggests management's confidence in the company's future growth and value creation, contingent on securing shareholder approval for the necessary plan amendment.

Management Comments

• The grant of 4,800,000 stock options to Samuel J. Reich, CEO and Executive Chairman, under the 2021 Omnibus Equity Incentive Plan, reflects a strategic move to incentivize long-term leadership performance and align executive interests with shareholder value creation.

Industry Context

Executive stock option grants are a common practice in the biotechnology and pharmaceutical industries to attract, retain, and motivate key leadership, particularly in companies focused on long-term research and development milestones. The size of the grant is significant, reflecting the CEO's dual role and the company's stage.

Comparison to Industry Standards

• The grant of 4.8 million stock options to a CEO in a biotech company like SAB Biotherapeutics is substantial, often seen in growth-oriented firms where long-term value creation is paramount. For instance, similar large grants have been observed in early-to-mid-stage biotech companies like Moderna (MRNA) or BioNTech (BNTX) during their growth phases, aiming to tie executive compensation directly to the successful development and commercialization of their pipelines.
• The four-year vesting schedule with a cliff and monthly installments is a standard industry practice designed to ensure executive retention and sustained performance over a multi-year horizon, comparable to compensation structures at companies such as Regeneron Pharmaceuticals (REGN) or Gilead Sciences (GILD) for their top executives.

Corporate Governance

Related Party Transactions

• The grant of 4,800,000 stock options to Samuel J. Reich, the CEO and Executive Chairman, constitutes a related party transaction as he is an insider of the company.

Stakeholder Impact

• **Shareholders:** Potential for long-term value creation if the CEO's incentives lead to increased stock price. However, there is a risk of dilution if the options are exercised.
• **Employees:** The grant is part of the company's overall equity incentive plan, which can impact employee morale and retention by demonstrating a commitment to performance-based compensation.

Next Steps

• The Company must seek and obtain stockholder approval to amend the 2021 Omnibus Equity Incentive Plan to increase the number of shares available for issuance, which is a condition for the full realization of these awards.

Key Dates

Recommendation

The Form 4 filing details a significant stock option grant to the CEO, which is a positive for aligning management incentives with shareholder interests. However, this is a compensation event rather than a direct operational or financial performance update. While it signals management's confidence, it also introduces potential future dilution and is contingent on shareholder approval. A single insider transaction, even a large one, typically does not warrant a change in a fundamental investment thesis, thus a 'hold' recommendation is appropriate to observe further developments and company performance.

Keywords

SAB Biotherapeutics, SABS, Stock Options, Executive Compensation, Form 4, Samuel J. Reich, Equity Incentive Plan, CEO, Director, Insider Transaction